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Abstract 
Background: An increase in myocardial collagen content may contribute to the development of heart 
failure; this might be inhibited or reversed by mineralocorticoid receptor antagonists (MRAs). We 
investigated changes in serum concentrations of the collagen synthesis biomarkers N-terminal 
propeptide of procollagen type III (PIIINP) (primary outcome) and C-terminal propeptide of 
procollagen type I (PICP) (secondary outcome) after non-randomized initiation of spironolactone as 
add-on therapy amongst patients with resistant hypertension enrolled in the “Anglo-Scandinavian 
Cardiac Outcomes” (ASCOT) trial. 
Methods: An age/sex matching plus propensity-scored logistic regression model incorporating 
variables related to the outcome and spironolactone treatment was created to compare patients treated 
with spironolactone for 9-month periods vs. matched controls. A within-person analysis comparing 
changes in serum biomarker concentrations in the 9-month before vs. after spironolactone treatment 
was also performed.  
Results: Patients included in the between-person analysis (n=146) were well matched: the mean age 
was 63±7 years and 11% were woman. Serum concentrations of PIIINP and PICP rose in “controls” 
and fell during spironolactone treatment (adjusted means +0.52 [-0.05 to 1.09] vs. -0.41 [-0.97 to 0.16] 
ng/mL, p=0.031 for PIIINP and +4.54 [-1.77 to 10.9] vs. -6.36 [-12.5 to -0.21] ng/mL, p=0.023 for 
PICP). For the within-person analysis (n=173), spironolactone treatment was also associated with a 
reduction in PICP (beta estimate = -11.82 [-17.53 to -6.10] ng/mL, p<0.001) but not in PIIINP levels. 
Conclusions: Treatment with spironolactone was associated with a reduction in serum biomarkers of 
collagen synthesis independently of blood pressure in hypertensive patients, suggesting that 
spironolactone might exert favorable effects on myocardial collagen synthesis and fibrosis. Whether 
this effect might contribute to slowing the progression to heart failure is worth investigating. 
 
Key-words: resistant hypertension; collagen markers; fibrosis; heart failure; spironolactone; 
prevention.  
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Key Messages 
What is already known about this subject? 
Spironolactone is the most effective add-on drug for the treatment of resistant hypertension. 
What does this study add? 
From a practical standpoint the present manuscript reinforces the current knowledge as it demonstrates 
that beyond its blood pressure lowering properties, spironolactone can reduce myocardial fibrosis and 
by this mechanism potentially delay heart failure onset. 
How might this impact on clinical practice? 
Spironolactone could be used not only for the lowering of blood pressure in patients with resistant 
hypertension but also for the reduction of myocardial fibrosis and potentially heart failure. 
Whether spironolactone should be added earlier in the treatment of hypertension requires prospective 
validation. 
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Abbreviation list: 
HF, heart failure 
BP, blood pressure 
CV, cardiovascular 
MRAs, mineralocorticoid receptor antagonists 
MI, myocardial infarction 
PIIINP, N-terminal propeptide of procollagen type III 
PICP, C-terminal propeptide of procollagen type I 
CITP, C-terminal telopeptide of collagen type I 
MMP-1, matrix-metalloproteinase-1 
NT-proBNP, N-terminal pro brain natriuretic peptide 
hsTnT, high-sensitivity troponin T 
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Introduction  
Heart failure (HF) is a serious and growing problem that impairs quality of life, causes 
recurrent hospitalizations and shortens life expectancy1 and thus greater efforts to delay or prevent its 
onset are justified2. For patients with hypertension, effective blood pressure (BP) control reduces the 
incidence of cardiovascular (CV) events3, 4, especially HF5.  
An increase in myocardial and vascular collagen content (“fibrosis”) is common in 
hypertensive patients and may be a major determinant of transition to and progression of HF6-9. 
Mineralocorticoid receptor antagonists (MRAs), such as spironolactone, are a highly effective 
treatment for resistant hypertension10 and also reduce plasma/serum biomarkers of collagen synthesis 
in patients with HF, myocardial infarction, and metabolic syndrome11-15. Whether MRAs also reduce 
collagen synthesis biomarkers in patients with hypertension and whether this is independent of their 
effect on blood pressure is unknown. If MRAs have such a dual mechanism of action, they could be 
particularly effective at preventing HF. 
Accordingly, we studied the effects of spironolactone on serum collagen metabolism 
biomarkers in a subset of patients with resistant hypertension that participated in the “Anglo-
Scandinavian Cardiac Outcomes” (ASCOT) trial16.  
 
Methods 
Trial design 
The design, patient eligibility criteria, study procedure and main results of the Anglo-
Scandinavian Cardiac Outcomes trial-blood pressure lowering arm (ASCOT-BPLA) have been 
previously reported17. In short, the ASCOT-BPLA was a multicentre, prospective, randomised 
controlled trial, enrolling 19,257 patients with hypertension who were aged 40–79 years and had at 
least three other cardiovascular risk factors. Patients were assigned either amlodipine adding 
perindopril as required (n=9,639) or atenolol adding bendroflumethiazide and potassium as required 
(n=9,618). Spironolactone, as a fourth-line agent for resistant hypertension, was evaluated in 1,411 
participants as add-on therapy prescribed in a non-randomized fashion at the discretion of the treating 
physician16. The median duration of spironolactone treatment was 1.3 years (interquartile range: 0.6 to 
2.6 years) and the median dose of spironolactone was 25 mg (interquartile range: 25 to 50 mg) at both 
the start and end of the observation period. Spironolactone reduced mean blood pressure by 22/10 
mmHg independently of age, sex, smoking, and diabetic status. Only patients treated with 
spironolactone for at least 9 months and with available serum samples were selected for this 
observational analysis, as it was thought that short-term intervention might have little or no effect on 
collagen turnover (please see also the methods section). Further patient selection for this analysis is 
shown in Figure 1.  
 6 
Ethical approval and signed informed consent were required to participate in the ASCOT trial. 
  
Study aims and biomarker assessment 
The main aims of this analysis were to compare changes in serum concentrations of N-
terminal propeptide of procollagen type III (PIIINP) – primary outcome measure and C-terminal 
propeptide of procollagen type I (PICP) – secondary outcome measure plus C-terminal telopeptide of 
collagen type I (CITP), matrix-metalloproteinase-1 (MMP-1), CITP/MMP-1 ratio, and PIIINP/CITP 
ratio – exploratory measures in spironolactone-treated patients vs. matched controls (between-person 
analysis). Additionally, a within-person analysis was performed by assessing the changes in the 
biomarker levels in spironolactone-treated patients (spironolactone period) compared to the 9 months 
prior to spironolactone treatment (control period) using the same outcome measures as above 
described. The use of PIIINP as primary outcome measure was chosen for testing the primary 
hypothesis of the HOMAGE (“Heart 'omics' in AGEing”) trial (NCT02556450) in which patients at 
high-risk for developing HF are randomized to either spironolactone plus conventional therapy or 
conventional therapy alone to assess the effect of spironolactone on PIIINP changes from baseline to 9 
months. The assessment of PICP changes as secondary outcome measure was based on the increasing 
body of evidence supporting the direct correlation of this biomarker with myocardial fibrosis18.  The 
evidence supporting the correlation of the other studied biomarkers with myocardial fibrosis is weaker 
and they were assessed as exploratory measures.  
The rationale for the use of the above referenced “ratios” is as follows: the CITP/MMP-1 ratio 
has been shown to be inversely correlated with myocardial collagen cross-linking in HF patients7. As 
collagen cross-linking determines the resistance of the collagen fiber to MMP degradation, the higher 
the cross-linking of collagen type I fibers, the lower the cleavage of the cross-linked peptide CITP by 
the enzyme MMP-1. The PIIINP/CITP ratio has been found to be associated with higher event-rate in 
patients with MI and it has been used as a way to evaluate the collagen turnover as it is a ratio between 
a synthesis and a degradation marker19.  
Changes in serum N-terminal pro brain natriuretic peptide (NT-proBNP) and high sensitive 
troponin T (hsTnT), were also assessed as exploratory analyses.  
The 9-month assessment visit was chosen based on the observation that in more “severe” and 
symptomatic populations (such as RALES and EPHESUS: HF-REF with severe symptoms and MI 
with systolic dysfunction, respectively) a lowering in collagen markers in patients randomized to 
MRA therapy was observed at 6 months12, 13, hence we hypothesize that less “severe” patients (such as 
those included in ASCOT and HOMAGE) spironolactone may require more time to demonstrate its 
“anti-fibrotic” effects. 
Blood samples were drawn at 9-month before spironolactone treatment (visit 1, V1), baseline 
(visit 2, V2; the first day of spironolactone treatment), and after 9-month of spironolactone treatment 
(visit 3, V3). All samples were centrifuged immediately at 3000 rpm for 10 minutes and stored at -
 7 
80°C until assay analysis. Samples were available for at least two time-points. All samples were 
transported to the central laboratory and assayed in 1 batch. All assays were performed by technicians 
blinded to clinical data and subject randomization. 
A commercial radioimmunoassay (Orion Diagnostica) was used to measure PIIINP. The lower 
limit of detection was 0.3 µg/L. Serum PICP was measured by using the METRA EIA kit (Quidel 
Corporation). The lower limit of detection was 0.2 µg/L. Inter-assay variability was <12% and intra-
assay variations was <10% for both. Serum NT-proBNP was measured using an ELISA method 
(Roche Diagnostics). The inter-assay and intra-assay coefficients of variation were less than 7% and 
the lower limit of detection was 5 pg/mL. Serum hsTnT was measured with a highly sensitive assay 
(Troponin T hs STAT, Roche Diagnostics). The lower detection limit of the assay was 0.005 g/L and 
the inter-assay coefficient of variation was 4.7%. Serum CITP was measured by ELISA (Orion 
Diagnostica). The inter-assay and intra-assay coefficients of variation were 9.4% and 11.2%. The 
lower limit of detection was 0.3 µg of CITP per liter. Total serum MMP-1 was measured by an ELISA 
method (GE Healthcare). The inter-assay and intra-assay coefficients of variation were 11.6% and 
5.5%, respectively and the lower limit of detection was 1.7 µg/L. 
 
Statistical analysis 
Continuous variables are expressed as mean ± standard deviation (SD) and median (percentile 
25-75). Categorical variables are presented was absolute numbers (n.) and frequencies (%). The studied 
biomarkers had a skewed distribution, however their “delta” (9-month value – baseline value) had 
normal distribution. Comparisons of patients` characteristics were performed using paired t-test, 
Wilcoxon signed-rank test or McNemar’s test as appropriate. Two analysis strategies were applied: 1) 
between-person analysis (i.e. spironolactone treated vs. matched controls) with 73 matched pairs 
identified. Figure 1; and 2) within-person analysis (i.e. comparison biomarker changes in the 9-month 
previous to spironolactone treatment [control period] vs. the 9-month after spironolactone treatment 
[spironolactone period]), with a total of 173 patients fulfilling this pattern. Figure 1. 
For the between-person analysis, spironolactone-treated vs. control patients were matched on 
age, sex and time since study participation. As the ASCOT study was not randomized according to 
spironolactone treatment, differences between spironolactone-treated patients and matched controls 
could still occur. In order to address this issue, we created a propensity score based on a logistic 
regression model that incorporated all variables independently associated both with the studied 
outcomes and the treatment decision. Smoking status, body mass index, systolic blood pressure, 
diastolic blood pressure, heart rate, total cholesterol, diabetes, study drug (amlodipine/atenolol) and 
initial value of NT-proBNP were used to compute the propensity score (an alternative propensity score 
was computed without baseline NT-proBNP for analyses evaluating the change in NT-proBNP). The 
generated propensity score was then used as adjustment variable. General linear models were 
performed to assess the association between spironolactone treatment and the change in biomarker 
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levels. For the within-person comparisons (control period vs. spironolactone period), each subject had 
3 biomarker values, allowing the computation of biomarker change in the 9 months before and after 
spironolactone treatment. Mixed models (repeated measures) were then used to assess biomarker 
changes. As the changes in biomarker levels may depend on the initial value of the biomarker, all 
analyses were adjusted on the biomarker initial value (i.e. the value of the biomarker at V1 when 
assessing the change between V1 and V2, and value of the biomarker at V2 when assessing the change 
between V2 and V3) plus the propensity score. For the between-person comparisons, each subject had 
only 1 value of biomarker change. Linear regression models were computed in this case, adjusted on 
the initial value of the biomarker plus the propensity score (as well as both variables age and gender 
which were involved in the matching) and an additional model was built with adjustment on systolic 
blood pressure changes. In the presence of outliers, the outcome values below the 5th and above the 
95th percentile were excluded (we also performed the same set of analyses in the whole population i.e. 
including outliers, with overlapping results; data not shown). Results are expressed as beta estimates 
and respective 95% confidence intervals. A p-value of <0.05 was considered statistically significant. 
All analyses were performed using software SAS version 9.4 (SAS Institute Inc., Cary, N.C., USA). 
 
Study flow-chart 
A total of 252 patients were selected based on their pattern of spironolactone treatment (i.e., at 
least 9-month of treatment plus available blood samples). For the analysis we required samples for at 
least two time-points (i.e. V2 + V3) for the between-person matched analysis, and at least three (i.e. 
V1 + V2 + V3) for the within-person analysis. This left 146 patients for the between- person analysis 
(73 “spironolactone-treated” vs. 73 “controls”), and 173 patients for the within-person analysis. Sixty-
seven patients had features allowing their incorporation in both between- and within-person analysis. 
Figure 2. 
 
Results 
Between-person analysis 
Patients` characteristics 
 A total of 146 (73 “cases” and 73 “controls) patients were included in the between-person 
analysis (matched on age, sex, and study participation time). The mean age was 63±7 years, and the 
great majority (89%) were men. Most baseline characteristics were similar, but patients initiated on 
spironolactone had higher systolic blood pressure (167±16 vs. 161±18 years), more often had diabetes 
(45.2% vs. 26.0%) and were more likely to have been assigned to atenolol (69.9% vs. 42.5%) rather 
than amlodipine (30.1% vs. 57.5%). Table 1.  
Biomarker change 
Serum concentrations of the collagen synthesis biomarkers PIIINP and PICP fell in 
spironolactone-treated patients but rose in matched controls (adjusted means of PIIINP change =0.52 
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[-0.05 to 1.09] for control vs. -0.41 [-0.97 to 0.16] for spironolactone, p=0.031 and adjusted means of 
PICP change =4.54 [-1.77 to 10.9] for control vs. -6.36 [-12.5 to -0.21] for spironolactone, p=0.023). 
Changes of borderline statistical significance were observed for the collagen degradation biomarker 
CITP (adjusted means =-1.19 [-2.06 to -0.32] for control vs. -0.03 [-0.88 to 0.81] for spironolactone, 
p=0.080). Accordingly, the collagen turnover index (PIIINP/CITP) suggested higher turnover on 
spironolactone (adjusted means =0.38 [0.14 to 0.63] for control vs. -0.01 [-0.24 to 0.22] for 
spironolactone, p=0.042). No significant changes in MMP1, CITP/MMP1 ratio, NT-proBNP, and 
hsTnT were observed. Table 2 and Figure 3. The absolute (i.e. non-adjusted) changes are presented in 
Supplemental Table 1. The additional models adjusted on systolic blood pressure changes (i.e. V3 – 
V2) are shown in Supplemental Table 3. This resulted in a non-significant indirect effect of 
spironolactone induced by BP changes on the outcomes (p >0.10 for each biomarker, data not shown). 
  
Within-person analysis 
Patients` characteristics 
 The 173 patients included in the within-person (i.e. comparison of the same individuals before 
and after spironolactone treatment) analysis were older (mean age =64±8 years) and more often 
women (19.7%) than the matched case-controls but serum biomarker concentrations were similar. 
Table 1. 
Biomarker change 
Periods of treatment with spironolactone (compared to the period without treatment) were 
associated with a serum PICP fall (adjusted means =3.63 [0.08 to 7.18] before spironolactone vs. -8.20 
[-11.7 to -4.7] on spironolactone, p<0.001). No significant changes were observed regarding the other 
collagen biomarkers. Serum NT-proBNP fell during spironolactone treatment (adjusted means = 33 
[16 to 50] for the period without spironolactone vs. -21 [-39 to -3] on spironolactone, p<0.001). Table 
2. The absolute (i.e. non-adjusted) changes are presented in the Supplemental Table 2. and the 
adjusted biomarker changes incorporating also the delta systolic blood pressure at the time of 
biomarker measurements (i.e. V2 – V1 and V3 – V2) showed similar results to those presented in 
Table 2 (data not shown). 
 
Discussion 
This analysis suggests that treating patients with resistant hypertension and additional risk 
factors with spironolactone may be associated with a fall in serum concentrations of PIIINP and PICP, 
markers of collagen synthesis, and an increase in CITP a marker of collagen degradation, which might 
reflect a favourable effect on extracellular matrix remodelling and myocardial fibrosis. These changes 
were independent from the effects of spironolactone on blood pressure. We speculate that these 
favourable effects on extracellular matrix remodelling in patients at high risk might translate into 
clinically meaningful benefits by slowing the transition to LV diastolic dysfunction, atrial and/or 
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ventricular arrhythmias and, ultimately, HF6, 20.  
Prolonged myocardial stress due to hypertension and other risk factors is thought to increase 
extracellular matrix (ECM) deposition, leading to fibrosis that may compromise myocardial function 
and impair electrical conduction favoring the advent of arrhythmias and HF6, 20, 21. Collagen synthesis 
is a dynamic process involving metabolically active myofibroblasts20. In this regard, PIIINP is released 
into the bloodstream after cleavage from procollagen type III22. Serum PIIINP correlates with 
myocardial collagen type III in HF patients of ischemic etiology and idiopathic dilated 
cardiomyopathy (DCM), and higher concentrations are associated with a worse prognosis23, 24. The 
evidence supporting the effect of spironolactone in reducing PIIINP levels in humans with systolic 
dysfunction is robust. In patients with DCM the reduction of the myocardial collagen (as assessed by 
left ventricular endomyocardial biopsy) after treatment with spironolactone was accompanied by a 
reduction in serum PIIINP concentrations25. In 261 HF patients with reduced left ventricular ejection 
fraction and severe symptoms enrolled in the Randomized Aldactone Evaluation Study (RALES), 
serum concentrations of PIIINP above median (>3.9 ng/mL) were associated with higher mortality 
rates (HR; 95%CI =2.36; 1.34-4.18) and serum PIIINP decreased in spironolactone treated patients 
from baseline to 6 months but not in those assigned to placebo12. In MI patients with systolic 
dysfunction and/or HF enrolled in the Eplerenone Post–Acute Myocardial Infarction Heart Failure 
Efficacy and Survival Study (EPHESUS)13, eplerenone also reduced serum PIIINP. In 134 patients 
with acute anterior ST elevation MI (STEMI), intravenous potassium canrenoate (the active metabolite 
of spironolactone) also reduced serum PIIINP26. More recently, the REMINDER trial assessed the 
effect of eplerenone initiated within 24 h of symptom-onset in patients with an acute STEMI without 
known HF27. In a subanalysis including 526 patients with collagen biomarkers measurements, only 
those with PIIINP levels above the median of 3.9 ng/mL had a significant reduction of this biomarker 
by eplerenone (as compared to placebo)11. The median baseline levels of PIIINP in the ASCOT trial 
(median =5 ng/mL, percentile25-75 =4-6 ng/mL) were similar to those reported in the REMINDER (=4 
ng/mL), EPHESUS (=4 ng/mL)13 and RALES (=4 ng/mL)12 trials, and lower than those reported for 
patients in a study of DCM (=6 ng/mL)23. Suggesting that collagen turnover may be similar across a 
range of cardiovascular diseases.  
Serum PICP levels are highly correlated with total myocardial collagen volume fraction 
(assessed in myocardial samples with collagen-specific staining) in patients with hypertension and 
HF28, 29. However, the effect of MRA on serum concentrations of PICP have been less reproducible 
and of smaller magnitude as compared to the effect of MRAs on PIIINP. In RALES, PICP levels were 
not significantly reduced by spironolactone12. In 80 patients with metabolic syndrome spironolactone 
(vs. placebo) decreased circulating PICP levels (and also PIIINP), and PICP change correlated with 
improvement in left ventricular systolic function assessed by echocardiographic strain14. In 113 
patients with obesity (body mass index ≥30 Kg/m2) without other comorbidities, spironolactone (vs. 
placebo) reduced serum PICP as well as PIIINP; change in PICP (but not PIIINP) was associated with 
 11 
improvement in left ventricular diastolic function15. However, these findings were not reproduced in 
patients with diabetic cardiomyopathy30 (and PICP was not available in the EPHESUS and 
REMINDER trials). Both in the between- and within-person analysis marked effects on the drop of 
PICP levels were observed. PICP originates during the conversion of procollagen type I to collagen 
type I in a 1:1 ratio, hence serum PICP concentrations are direct indicators of collagen synthesis22.  
CITP is cleaved by the action of MMP-1 on collagen type I fibers and may reflect collagen 
type I degradation, however its association with myocardial fibrosis is not well established22. The 
CITP/MMP-1 ratio did not significantly change with spironolactone treatment, suggesting that 
spironolactone did not affect collagen cross-linking in the present analysis7. The PIIINP (collagen type 
III synthesis) to CITP (collagen type I degradation) ratio may serve as an indirect marker of collagen 
turnover19. Spironolactone may have had a beneficial effect on collagen turnover (i.e. less synthesis 
and more degradation) in this analysis. 
NT-proBNP fell with spironolactone in the within-person analysis. This may reflect a 
reduction in myocardial stress due to the reduction in blood pressure, a contraction in blood volume 
due to natriuresis, improved myocardial function due potassium retention as well as effects on 
collagen metabolism. The failure to observe an effect of spironolactone in the between-patient analysis 
may reflect the greater heterogeneity in NT-proBNP between patients. Serum concentrations of 
troponin were low and did not change in either analysis.  
The ongoing HOMAGE trial (NCT02556450) is investigating whether spironolactone 
(compared to “control”) can favorably alter extra-cellular matrix remodeling, assessed by changes in 
circulating PIIINP (primary outcome), PICP, NT-proBNP and echocardiographic measures from 
randomization to 9 months, in patients at increased risk of developing HF2, 31. This analysis provides 
some preliminary evidence to support the HOMAGE hypothesis. However, the widespread use of 
MRAs for the prevention of HF cannot be recommended until adequately powered studies 
demonstrate clinical benefits. Targeting patients with elevated serum concentrations of PIIINP and 
PICP indicating an active “pro-fibrotic” profile may increase efficacy and avoid a potentially 
hazardous treatment for patients who have little to gain. 
Clinical implications 
 Spironolactone is the most effective add-on drug for the treatment of resistant hypertension
10
. 
From a practical standpoint the present manuscript reinforces the current knowledge as it demonstrates 
that beyond its blood pressure lowering properties, spironolactone can reduce myocardial fibrosis and 
by this mechanism potentially delay HF onset. Therefore, spironolactone could be used not only for 
the lowering of blood pressure in patients with resistant hypertension but also for the reduction of 
myocardial fibrosis and potentially HF. Whether spironolactone should be added earlier in the 
treatment of hypertension requires prospective validation. 
 
Limitations 
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 Several limitations should be acknowledged in this analysis. This is a post-hoc study and the 
treatment of interest was not randomized; hence caution should be exercised in inferring any causal 
relationship and all the limitations inherent to observational studies are also applied herein. However, 
the study adds to a growing body of, as yet, inconclusive evidence. The propensity score technique 
cannot include unmeasured potential confounders. The between-person analysis also carries important 
confounders such as treatment effects and events that change over time within the same individual and 
that cannot be estimated separately. These findings lack external validation and should be 
prospectively confirmed in other cohorts (as in the ongoing HOMAGE program). Internal validation 
also showed caveats as PIIINP fell in patients treated with spironolactone in the between-person 
analysis but not in the within-person analysis. This may be due to bias and limitations inherent to these 
two approaches. Moreover, no imaging evaluation was available; hence we cannot ascertain if the 
changes in the collagen turnover biomarkers was accompanied by an improvement in cardiac structure 
and function. As the biomarker measurements were performed at only two or three time-points in 
order to evaluate our hypothesis, no kinetic of the effect of spironolactone could be assessed, therefore 
we cannot ascertain whether these changes were present before the 9-month measurement. 
Echocardiography was not routinely performed in the ASCOT trial; hence this information was not 
available for the present analysis. Echocardiographic variables could have provided further insight on 
whether these collagen marker changes were actually accompanied by improvements in the heart 
structure and function. Finally, we do not know how large a change in collagen turnover biomarkers is 
clinically relevant. 
 
Conclusions 
 Spironolactone, independently of blood pressure changes, was associated with a reduction in 
serum collagen synthesis biomarkers in patients with resistant hypertension, suggesting a potential 
beneficial effect of spironolactone on the cardiac extracellular matrix of this population at high-risk of 
developing HF. Further randomized trials are needed to properly assess this potential and, if so, 
whether such changes translate to clinical benefits to prevent new onset HF.   
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Table 1. Characteristics of the patients in the between-person (“spironolactone” / “control”) and within-person analysis 
 Between-person Within-person 
Patients` characteristics 
  
Matched control (N=73) Spironolactone (N=73) 
  
 
  
N   N    p* N   
Age, years 73 63 ± 7 73 63 ± 7 - 173 64 ± 8 
Women, n (%) 73 8 (11.0%) 73 8 (11.0%) - 173 34 (19.7%) 
Smoking status, n (%) 73 - 73 - 0.28 173 - 
    Current smoker - 16 (21.9%) - 19 (26.0%) - - 31 (17.9%) 
    Past smoker - 39 (53.4%) - 30 (41.1%) - - 73 (42.2%) 
Body mass index, kg/m² 73 28.7 ± 4.5 73 30.0 ± 4.1 0.081 173 30.1 ± 4.4 
SBP, mmHg 73 161 ± 16 73 167 ± 18 0.035 173 167 ± 19 
DBP, mmHg 73 93 ± 9 73 93 ± 11 0.91 173 92 ± 11 
Heart rate, bpm 73 72 ± 11 73 74 ± 15 0.23 173 71 ± 14 
Cholesterol, mmol/L 73 5.8 ± 1.1 73 5.8 ± 1.1 0.82 173 5.8 ± 1.1 
LDL, mmol/L 69 3.7 ± 1.1 69 3.6 ± 1.0 0.41 163 3.7 ± 1.0 
eGFR, mL/min/1.73m² 45 72 (61 - 79) 50 72 (62 - 78) 0.46 121 70 (62 - 77) 
Potassium, mmol/L 67 4.2 ± 0.4 73 4.3 ± 0.5 0.56 165 4.2 ± 0.6 
Blood glucose, mmol/L 70 5.7 (5.2 - 6.7) 70 6.1 (5.3 - 7.8) 0.31 166 6.0 (5.2 - 7.9) 
Diabetes, n (%) 73 19 (26.0%) 73 33 (45.2%) 0.020 173 80 (46.2%) 
Study drug, n (%) 73 - 73 - 0.0009 173 - 
    Amlodipine - 42 (57.5%) - 22 (30.1%) - - 53 (30.6%) 
    Atenolol - 31 (42.5%) - 51 (69.9%) - - 120 (69.4%) 
ACE inhibitor, n (%) 69 25 (36.2%) 70 30 (42.9%) 0.49 168 61 (36.3%) 
ARB, n (%) 69 4 (5.8%) 70 5 (7.1%) 1.00 168 10 (6.0%) 
Beta blocker, n (%) 69 26 (37.7%) 70 26 (37.1%) 1.00 168 71 (42.3%) 
Thiazide diuretics, n (%) 69 28 (40.6%) 70 27 (38.6%) 0.86 168 69 (41.1%) 
LVH, n (%) 73 20 (27.4 %) 73 18 (24.7 %) 0.71 173 45 (26.0%) 
 19 
PIIINP, ng/mL 73 4.5 (3.7 - 6.3) 71 5.1 (3.6 - 6.4) 0.90 171 4.9 (3.7 - 6.3) 
PICP, ng/mL 68 76 (63 - 90) 68 80 (66 - 102) 0.076 166 78 (66 - 100) 
CITP, ng/mL 68 5.9 (3.3 - 9.1) 68 7.1 (4.4 - 8.9) 0.29 166 6.4 (4.2 - 8.8) 
PIIINP/CITP ratio 68 0.90 (0.49 - 1.58) 67 0.73 (0.49 - 1.33) 0.33 165 0.77 (0.52 - 1.33) 
MMP1, ng/mL 68 5.5 (4.4 - 9.1) 68 5.9 (5.1 - 10.0) 0.60 166 6.2 (5.0 - 10.2) 
CITP/MMP1 ratio 68 2.76 (1.55 - 5.25) 68 3.23 (1.78 - 4.73) 0.44 166 3.16 (1.36 - 4.94) 
NT-proBNP, pg/mL 70 95 (48 - 239) 71 168 (66 - 324) 0.051 166 176 (87 - 354) 
hsTnT, pg/mL 71 9 (6 - 14) 71 10 (7 - 13) 0.82 166 10 (7 - 14) 
* paired t-test for normal variables, wilcoxon signed-rank test for skewed variables, McNemar's test for categorical variables. 
Clinical data correspond to information available at the inclusion visit in the ASCOT-BPLA trial.  
Biomarker data presented in the table are those available at V2.  
Legend: SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density cholesterol; eGFR, estimated glomerular filtration rate; ACE, angiotensin converting 
enzyme; ARB, angiotensin receptor blocker; LVH, left ventricular hypertrophy based on information from investigator electrocardiogram; PIIINP, N-Terminal Propeptide of 
Type III Collagen; PICP, procollagen I carboxyterminal propeptide; CITP, carboxyl-terminal telopeptide of collagen type I; MMP1, matrix-metalloproteinase  1;  NT-pro 
BNP, N-terminal pro brain natriuretic peptide; hsTnT, high-sensitivity troponin T.
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Table 2. Matched- and within-person biomarker adjusted changes  
 
Adjusted mean of the absolute change and its 95%CI 
Matched between-person analysis* 
Studied biomarker beta estimate (95%CI) p Control group Spironolactone group 
PIIINP, ng/mL -0.93 [-1.77 ; -0.09] 0.031 0.52 [-0.05 ; 1.09] -0.41 [-0.97 ; 0.16] 
PICP, ng/mL -10.9 [-20.3 ; -1.50] 0.023 4.54 [-1.77 ; 10.9] -6.36 [-12.5 ; -0.21] 
CITP, ng/mL 1.16 [-0.14 ; 2.45] 0.080 -1.19 [-2.06 ; -0.32] -0.03 [-0.88 ; 0.81] 
PIIINP/CITP ratio -0.39 [-0.75 ; -0.03] 0.034 0.38 [0.14 ; 0.63] -0.01 [-0.24 ; 0.22] 
MMP1, ng/mL -0.10 [-0.54 ; 0.35] 0.66 0.23 [-0.06 ; 0.53] 0.14 [-0.16 ; 0.43] 
CITP/MMP1 ratio 0.09 [-0.55 ; 0.73] 0.78 -0.38 [-0.82 ; 0.06] -0.29 [-0.70 ; 0.13] 
NTproBNP, pg/mL 11.9 [-74.4 ; 98.3] 0.78 26.3 [-32.6 ; 85.2] 38.2 [-19.2 ; 95.6] 
hsTnT, pg/mL 0.41 [-1.40 ; 2.22] 0.65 0.56 [-0.68 ; 1.80] 0.97 [-0.23 ; 2.17] 
Within-person analysis** 
Studied biomarker beta estimate (95%CI) p Control period Spironolactone period 
PIIINP, ng/mL -0.27 [-0.78 ; 0.25] 0.31 0.08 [-0.25 ; 0.40] -0.19 [-0.50 ; 0.12] 
PICP, ng/mL -11.8 [-17.5 ; -6.1] < 0.0001 3.63 [0.08 ; 7.18] -8.2 [-11.7 ; -4.7] 
CITP, ng/mL 0.20 [-0.65 ; 1.06] 0.64 -0.45 [-0.97 ; 0.08] -0.24 [-0.76 ; 0.28] 
PIIINP/CITP ratio -0.36 [-1.20 ; 0.49] 0.41 0.28 [-0.27 ; 0.82] -0.08 [-0.61 ; 0.45] 
MMP1, ng/mL -0.06 [-0.55 ; 0.42] 0.79 -0.05 [-0.37 ; 0.26] -0.12 [-0.43 ; 0.19] 
CITP/MMP1 ratio -0.01 [-0.67 ; 0.66] 0.99 -0.22 [-0.62 ; 0.17] -0.23 [-0.62 ; 0.16] 
NTproBNP, pg/mL -53.8 [-82.1 ; -25.4] 0.0003 32.8 [15.5 ; 50.1] -20.9 [-39.0 ; -2.86] 
hsTnT, pg/mL -0.36 [-1.44 ; 0.72] 0.51 0.80 [0.18 ; 1.43] 0.44 [-0.18 ; 1.07] 
*Models adjusted on V2 biomarker levels, age, gender and propensity score. 
**Models adjusted on V1 biomarker levels for control period and V2 biomarker levels for spironolactone period. 
Legend: PIIINP, N-Terminal Propeptide of Type III Collagen; PICP, procollagen I carboxyterminal propeptide; CITP, carboxyl-terminal telopeptide of collagen type I; 
MMP1, matrix-metalloproteinase  1;  NT-pro BNP, N-terminal pro brain natriuretic peptide; hsTnT, high-sensitivity troponin T.
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